氧化DNA损伤相关疾病，如无法治愈的炎症、恶性肿瘤和年龄相关疾病，由于其复杂的分子机制和识别有效治疗靶点的局限性，给现代医学带来了重大挑战。最近，8-氧代鸟嘌呤 DNA 糖基化酶 1 (OGG1) 已成为治疗这些具有挑战性的疾病的有前途的多功能治疗靶点。在这篇综述中，我们系统地总结了OGG1的多种功能和机制，包括促炎、致瘤和衰老调节机制。我们还强调 OGG1 抑制剂和激活剂作为上述限制生命疾病的有效治疗剂的潜力。我们得出结论，OGG1 充当多功能枢纽；抑制OGG1可能为预防和治疗炎症和癌症提供一种新方法，而激活OGG1可能是预防与年龄相关的疾病的策略。此外，我们还广泛概述了 OGG1 调节在治疗炎症、癌症和衰老相关疾病中的成功应用。最后，我们讨论了 OGG1 作为上述挑战性疾病的新兴多功能治疗标志物当前面临的挑战和未来方向。本综述的目的是为科研人员和临床药物研发人员开发针对生命有限疾病，特别是针对无法治愈的炎症、恶性肿瘤和年龄相关疾病的新型临床靶向药物提供有力的参考。© 2024 作者（s）。医学研究评论由 Wiley periodicals LLC 出版。

Oxidative DNA damage-related diseases, such as incurable inflammation, malignant tumors, and age-related disorders, present significant challenges in modern medicine due to their complex molecular mechanisms and limitations in identifying effective treatment targets. Recently, 8-oxoguanine DNA glycosylase 1 (OGG1) has emerged as a promising multifunctional therapeutic target for the treatment of these challenging diseases. In this review, we systematically summarize the multiple functions and mechanisms of OGG1, including pro-inflammatory, tumorigenic, and aging regulatory mechanisms. We also highlight the potential of OGG1 inhibitors and activators as potent therapeutic agents for the aforementioned life-limiting diseases. We conclude that OGG1 serves as a multifunctional hub; the inhibition of OGG1 may provide a novel approach for preventing and treating inflammation and cancer, and the activation of OGG1 could be a strategy for preventing age-related disorders. Furthermore, we provide an extensive overview of successful applications of OGG1 regulation in treating inflammatory, cancerous, and aging-related diseases. Finally, we discuss the current challenges and future directions of OGG1 as an emerging multifunctional therapeutic marker for the aforementioned challenging diseases. The aim of this review is to provide a robust reference for scientific researchers and clinical drug developers in the development of novel clinical targeted drugs for life-limiting diseases, especially for incurable inflammation, malignant tumors, and age-related disorders.© 2024 The Author(s). Medicinal Research Reviews published by Wiley Periodicals LLC.